Pharmacologic class (EPC) · 2 drug pages

Vascular endothelial growth factor receptor 2 antagonist: adverse event reports filed with FDA

5,658 reports list a drug in this class as a suspect or interacting product, 2010–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

5,658
reports across the class: 0% of all reports; 331
reports, 12 months to June 2026: 385 in the 12 months before; 94%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Vascular endothelial growth factor receptor 2 antagonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 5,658 adverse event reports received by FDA, 0% of the database, from October 2010 to June 2026.

331 reports arrived in the 12 months to June 2026, down 14% from 385 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 94% of the class's reports are marked serious, 27% record death among the outcomes and 38.7% record hospitalisation, as reported.

Across the class the reactions recorded most often are malignant neoplasm progression (13.5%), death (9.5%) and interstitial lung disease (4.9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
CyramzaRamucirumab	brand	3,967	195	91.9%	Malignant neoplasm progression
Ramucirumab	generic	1,691	136	99%	Malignant neoplasm progression

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Malignant neoplasm progression13.5%766
Deaththe patient died; cause not stated by this term9.5%535
Interstitial lung diseasescarring or inflammation of lung tissue4.9%277
Neutropenialow neutrophils, a type of white blood cell4.1%233
Febrile neutropeniafever with low white blood cells4%229
Decreased appetitereduced appetite3.4%195
Diarrhoealoose or frequent stools3.4%195
Hypertensionhigh blood pressure3.2%180
Nauseafeeling sick3%168
Fatiguetiredness2.9%165
Pyrexiafever2.9%164
Ascitesfluid in the abdomen2.8%159
Off label useused for a purpose or in a way not on the label2.8%157
Disease progressionthe disease advanced2.8%156
Neutrophil count decreased2.7%150
Pneumonialung infection2.5%144
Neuropathy peripheralnerve damage in hands or feet2.5%141
Anaemialow red blood cells2.4%134
Drug ineffectivethe medicine did not work as expected2.4%134
Proteinuriaprotein in the urine2.2%125
Dyspnoeashortness of breath2.1%118
Abdominal painstomach or belly pain2%115
Vomitingbeing sick2%115
Malaisegeneral feeling of being unwell1.7%99
Platelet count decreasedlow platelet count1.7%99

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death27%1,529

Life-threatening5.5%314

Hospitalisation (initial or prolonged)38.7%2,187

Disability1.7%98

Congenital anomaly0%1

Other serious52.9%2,995

Not serious6%340

Patient age

Under 20%1

2 to 110%0

12 to 170.6%36

18 to 444.7%264

45 to 6424.8%1,401

65 to 7426.7%1,509

75 and over15%846

Age not given28.3%1,601

Who reported

Physician26.8%1,518

Pharmacist6.1%346

Other health professional15.9%902

Lawyer0.1%3

Consumer or non-health professional50.3%2,844

Not given0.8%45

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Vascular endothelial growth factor receptor 2 antagonist reports

Which drugs are in the Vascular endothelial growth factor receptor 2 antagonist class on this site?

Cyramza and Ramucirumab. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

5,658 reports through June 2026, 331 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

malignant neoplasm progression (13.5%), death (9.5%), interstitial lung disease (4.9%), neutropenia (4.1%) and febrile neutropenia (4%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.